Conference Coverage of CROI 2022: Clinical Impact of New HIV Data*

Despite having a favorable safety profile, the heterologous Imbokodo HIV-1 vaccine regimen did not provide statistically significant protection against HIV-1 among younger women at high risk for HIV-1 acquisition in sub-Saharan Africa.

Despite ART intensification in the treatment arms, performance on neuropsychologic testing improved similarly in all arms, including placebo, consistent with the practice effect.

Favorable outcomes observed for PWH with virologic failure receiving 3TC/TDF/NNRTI switching to DTG plus either FTC/TAF or 3TC/TDF.

This trial supports use of DTG + 2 NRTIs as second-line ART, even if NRTIs are predicted to have no activity, but resistance is a concern.

Two regimens featuring a subcutaneous lenacapavir backbone administered every 6 months conferred complete virologic suppression in 85% to 90% of patients at Week 54.

Using stringent criteria of HIV-1 RNA <40 copies/mL and target not detected, proportions of patients with BL archived resistance mutations who responded were similar with DTG/3TC vs continued 3-drug ART at Week 48.

Lenacapavir in combination with an optimized background regimen associated with virologic suppression in 83% of patients, 1 injection site reaction leading to discontinuation.

Implant sustained release of ARV above viral replication inhibition thresholds in a mouse model; no difference in ARV release when coformulated with either of 2 contraceptives.

No clinically meaningful differences in metabolic and renal parameters observed between monthly oral placebo and islatravir for PrEP through 24 weeks.

Additional 1 year of unblinded follow-up of HPTN 083 study continues to support superiority of long-acting injectable cabotegravir vs daily oral FTC/TDF in reducing incident HIV infection among MSM and TGW at high risk of HIV infection.